LTRN Projected Dividend Yield

Lantern Pharma Inc ( NASDAQ : LTRN )

Lantern Pharma is a biotechnology company, focused on utilizing artificial intelligence, machine learning and genomic data. Co.'s drug candidates include: LP-300, which is a cysteine-modifying molecular entity that works to modulate multiple cellular pathways and is a combination agent for targeted indications in non-small cell lung cancer; LP-184, which preferentially damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways; LP-284, which is for the treatment of several non-Hodgkin's lymphomas including mantle cell lymphoma and double hit lymphoma; and LP-100, which exploits cancer cells' deficiency in DNA repair mechanisms.

20 YEAR PERFORMANCE RESULTS